Literature DB >> 11906488

Pharmacological profile of nociceptin/orphanin FQ receptors.

Girolamo Calo'1, Anna Rizzi, Raffaella Bigoni, Remo Guerrini, Severo Salvadori, Domenico Regoli.   

Abstract

1. Nociceptin/orphanin FQ (NC) and its receptor (OP4) represent a novel peptide/receptor system pharmacologically distinct from classical opioid systems. 2. Via OP4 receptor activation, NC regulates several biological functions, both at peripheral and central levels; therefore, the OP4 receptor may be viewed as a novel target for drug development. However, the pharmacology of this receptor is still in its infancy, with few molecules interacting selectively with this receptor. 3. In the present article, we review the findings of studies that have investigated the pharmacological profile of ligands selective for the OP4 receptor, these being two antagonists, the peptide [Nphe1]NC(1-13)NH2 and the non-peptide J-113397, and two agonists, the peptide [Arg14,Lys15]NC, and the non- peptide Ro 64-6198. 4. The results of these studies indicate that agents that selectively activate or block the OP4 receptor may represent new potential drugs for the treatment of human diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11906488     DOI: 10.1046/j.1440-1681.2002.03633.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  13 in total

1.  Nociceptin produces antinociception after spinal administration in amphibians.

Authors:  Craig W Stevens; Kristin K Martin; Brad W Stahlheber
Journal:  Pharmacol Biochem Behav       Date:  2008-09-05       Impact factor: 3.533

2.  Modification of anxiety-like behaviors by nociceptin/orphanin FQ (N/OFQ) and time-dependent changes in N/OFQ-NOP gene expression following ethanol withdrawal.

Authors:  Harinder Aujla; Rosalia Cannarsa; Patrizia Romualdi; Roberto Ciccocioppo; Rémi Martin-Fardon; Friedbert Weiss
Journal:  Addict Biol       Date:  2012-07-15       Impact factor: 4.280

3.  ∆(9)-Tetrahydrocannabinol decreases NOP receptor density and mRNA levels in human SH-SY5Y cells.

Authors:  Rosalia Cannarsa; Donatella Carretta; Francesca Lattanzio; Sanzio Candeletti; Patrizia Romualdi
Journal:  J Mol Neurosci       Date:  2011-05-21       Impact factor: 3.444

4.  The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands.

Authors:  Ling Jong; Nurulain Zaveri; Lawrence Toll
Journal:  Bioorg Med Chem Lett       Date:  2004-01-05       Impact factor: 2.823

Review 5.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

6.  Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ.

Authors:  Dirk Faulhammer; Bernd Eschgfäller; Sandra Stark; Petra Burgstaller; Werner Englberger; Jeannette Erfurth; Frank Kleinjung; Johanna Rupp; Sebastian Dan Vulcu; Werner Schröder; Stefan Vonhoff; Hermann Nawrath; Clemens Gillen; Sven Klussmann
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

Review 7.  Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands.

Authors:  Elaine C Gavioli; Girolamo Calo'
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02-21       Impact factor: 3.000

8.  Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex.

Authors:  Matteo Marti; Sara Stocchi; Francesca Paganini; Flora Mela; Carmela De Risi; Girolamo Calo'; Remo Guerrini; Timothy A Barnes; David G Lambert; Lorenzo Beani; Clementina Bianchi; Michele Morari
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

9.  Increased nociceptin/orphanin FQ plasma levels in hepatocellular carcinoma.

Authors:  Ferenc Szalay; Monika B Hantos; Andrea Horvath; Peter L Lakatos; Aniko Folhoffer; Kinga Dunkel; Dalma Hegedus; Kornelia Tekes
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

Review 10.  Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.

Authors:  Andrea Kurz; Daniel I Sessler
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.